Stereotactic biopsy of brainstem lesions yields diagnosis in 93.5% with 0.30% procedure-related mortalityStereotactic biopsy shows high success for brainstem lesion diagnosis

Frontiers in Medicine Published September 11, 2026 DOI ↗ Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider stereotactic biopsy for brainstem lesions given 93.5% diagnostic yield, but individualize due to 10.5% complications.

This meta-analysis synthesized data on stereotactic biopsy for brainstem lesions, pooling diagnostic yield and safety outcomes across studies. The primary outcome, diagnostic yield, was 93.5% (1,814/1,956; 95% CI, 91.5%-95.0%). When studies with fewer than 20 participants were excluded, yield was 93.7% (95% CI, 91.3%-95.5%).

Safety outcomes included overall complications in 10.5% (162/1,797; 95% CI, 8.5%-12.8%), permanent neurological morbidity in 0.83% (14/859; 95% CI, 0.22%-3.03%), and procedure-related mortality in 0.30% by GLMM estimate (11/1,765; 95% CI, 0.31%-1.11% crude; 95% CI, 0.07%-1.24% GLMM). Molecular clinical utility was also assessed, but the authors note heterogeneous constructs and denominators.

The authors acknowledge several limitations: inaccurate estimation of permanent morbidity due to small sample sizes in some studies, and an inverse association between observed yield and study size. Follow-up duration and funding or conflicts of interest were not reported.

The results support cautious individualized interpretation rather than a universal recommendation, given variability in population, era, technique, and outcome definitions. Clinicians should weigh the high diagnostic yield against the low but non-zero risks of permanent morbidity and procedure-related mortality when considering stereotactic biopsy for brainstem lesions.

When doctors need to find out exactly what is causing a lesion in the brainstem, they often turn to a procedure called a stereotactic biopsy. This method helps them get a clear diagnosis while trying to keep the patient as safe as possible. Recent data shows that this technique has a high diagnostic yield, meaning it successfully identifies the issue in the vast majority of cases.

In a review of nearly 2,000 cases, the procedure successfully provided a diagnosis in about 93.5% of instances. While the procedure did lead to some complications, the rate of overall complications was about 10.5%. Even more importantly, the risk of permanent neurological damage was very low, affecting less than 1% of the patients studied.

While the results are encouraging, doctors suggest that every case is unique. Because different hospitals use different techniques and face different patient needs, the results should be interpreted carefully for each individual. The data confirms that while the procedure is highly effective at providing answers, it requires careful, personalized planning by a medical team.

What this means for you:

Stereotactic biopsy is highly effective at diagnosing brainstem lesions with a very low risk of permanent damage.

Common questions

How successful is a stereotactic biopsy at finding the cause of a brainstem lesion?

The procedure has a high diagnostic yield. In the data reviewed, it successfully provided a diagnosis in 1,814 out of 1,956 cases, which is a success rate of about 93.5%.

Is the procedure safe for patients with brainstem issues?

The procedure is generally well-tolerated. While there were some complications, the rate of overall complications was 10.5%. The risk of permanent neurological damage was very low, occurring in only about 0.83% of cases.

What is the risk of death during the procedure?

The risk of procedure-related mortality is very low. The data shows a mortality rate of approximately 0.30% based on a specialized statistical estimate (GLMM) from the cases reviewed.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedSep 2026

View Original Abstract ↓

Background/objectivesStereotactic biopsy of brainstem lesions must balance diagnostic and molecular information against procedure-related neurological risk. We updated the evidence base after a reviewer-directed literature coverage and overlap audit.MethodsThis PRISMA 2020 systematic review and meta-analysis was registered in PROSPERO (CRD420261432357). Searches covered English and Chinese bibliographic databases, trial registries, and Google Scholar, with forward and backward citation tracking during revision. Diagnostic yield and overall complications were analyzed with logit random-effects models; permanent neurological morbidity and procedure-related mortality were analyzed with binomial-normal generalized linear mixed models (GLMMs). Molecular clinical utility was synthesized narratively because its constructs and denominators were heterogeneous.ResultsSeventy-six reports met review-level eligibility (71 full-text and 5 abstract/conference reports), and 55 independent studies contributed to at least one preferred quantitative synthesis. Diagnostic yield was 1,814/1,956, with a pooled estimate of 93.5% (95% CI, 91.5%–95.0%). Overall complications were 162/1,797, with a pooled estimate of 10.5% (95% CI, 8.5%–12.8%). Permanent neurological morbidity was reported in 17 compatible studies (14/859; GLMM 0.83%, 95% CI, 0.22%–3.03%). Procedure-related mortality was 11/1,765 (crude 0.62%, exact 95% CI, 0.31%–1.11%); the primary GLMM estimate was 0.30% (95% CI, 0.07%–1.24%), whereas continuity-corrected models produced higher estimates. Diagnostic yield remained 93.7% (95% CI, 91.3%–95.5%) after excluding studies with fewer than 20 participants, although observed yield was inversely associated with study size.ConclusionsIn selected published cohorts, stereotactic biopsy provided high diagnostic yield. Overall complications were clinically meaningful, while observed procedure-related mortality was below 1% and permanent morbidity was uncommon but imprecisely estimated. Population, era, technique, outcome definition, and small-study analyses support cautious individualized interpretation rather than a universal biopsy recommendation.PROSPERO registrationCRD420261432357

Stereotactic biopsy of brainstem lesions yields diagnosis in 93.5% with 0.30% procedure-related mortalityStereotactic biopsy shows high success for brainstem lesion diagnosis

Common questions

Study Details

Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation

Potent bisphosphonates may lower fracture risk after denosumab treatment stops

Clinical research that matters. Delivered to your inbox.

Stereotactic biopsy of brainstem lesions yields diagnosis in 93.5% with 0.30% procedure-related mortalityStereotactic biopsy shows high success for brainstem lesion diagnosis

Common questions

Study Details

Potent bisphosphonate therapy reduces incident vertebral fractures by 71% after denosumab discontinuation

Potent bisphosphonates may lower fracture risk after denosumab treatment stops

Clinical research that matters. Delivered to your inbox.

Related in Orthopedics & Sports Medicine

From Other Specialties